Selumetinib-based therapy in uveal melanoma patient-derived xenografts

• Published in: Oncotarget Vol. 9; no. 31; pp. 21674 - 21686
• Main Authors: Decaudin, Didier, El Botty, Rania, Diallo, Béré, Massonnet, Gerald, Fleury, Justine, Naguez, Adnan, Raymondie, Chloé, Davies, Emma, Smith, Aaron, Wilson, Joanne, Howes, Colin, Smith, Paul D, Cassoux, Nathalie, Piperno-Neumann, Sophie, Roman-Roman, Sergio, Némati, Fariba
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 24-04-2018
• Subjects: Research Paper; targeted therapies; selumetinib; pharmacodynamics; uveal melanoma; patient-derived xenografts
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.24670

The prognosis of metastatic uveal melanoma (UM) is among the worst of all human cancers. The identification of near-ubiquitous GNAQ/GNA11 mutations and the activation of MAPK signaling in UM have raised hopes of more effective, targeted therapies, based on MEK inhibition, for example. We evaluated the potential of drug combinations to increase the efficacy of the MEK inhibitor selumetinib (AZD6244, ARRY-142886), in UM cell lines and Patient-Derived Xenografts. We first evaluated the combination of selumetinib and DTIC. We found that DTIC did not improve the
or
antitumor efficacy of selumetinib, consistent with the outcome of the SUMIT clinical trial assessing the efficacy of this combination in UM. We then tested additional selumetinib combinations with the chemotherapy agent docetaxel, the ERK inhibitor AZ6197, and the mTORC1/2 inhibitor, vistusertib (AZD2014). Combinations of selumetinib with ERK and mTORC1/2 inhibitors appeared to be the most effective in UM PDX models.